My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
TOJA-CAMBA, FJ; RODRIGUEZ-RODRIGUEZ, MP and GRANDIO-LEIVAS, L. Therapeutic management of invasive aspergillosis in a transplant patient and isavuconazole as a new antifungal alternative. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.4, pp.425-427. Epub Sep 19, 2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x20210004000017.
Opportunistic infections in patients undergoing solid organ transplantation (TOS) are a very important cause of morbidity and mortality. Among them, fungal infections, stand out for their higher mortality. One of the most frequent fungal infections is caused by Aspergillus. There are more than 150 species of Aspergillus, being Aspergillus fumigatus the most common agent of invasive fungal infections in human. Gold standard treatment for invasive aspergillosis in a patient withTOS is voriconazole.
We present the case of a kidney transplanted and immunocompromised patient with severe sepsis of respiratory origin in context of invasive aspergillosis. Interest of this case lies on the multiple pharmaceutical interventions in the patient's complex pharmacological management throughout his stay in the critics unit and satisfactory treatment with isavuconazole, a new antifungal.
Keywords : Aspergillus; transplants; sepsis.